Emu NL 06

Introduction

  1. The Panel, Costas Condoleon, Teresa Dyson and Karen Phin (sitting President), declined to make a declaration of unacceptable circumstances in relation to the affairs of Emu. The application concerned a placement announced 2 weeks before, and undertaken 1 week before, Emu’s AGM at which resolutions concerning the composition of the board were to be considered.

Wiluna Mining Corporation Limited

Introduction

  1. The Panel, Sylvia Falzon, Jon Gidney and Michael Lishman (sitting President) declined to conduct proceedings on an application by AIM Mining Corporation Limited in relation to the affairs of Wiluna Mining Corporation Limited. The application concerned an alleged undisclosed association between certain Wiluna shareholders who collectively held approximately 44.05% of Wiluna shares and were said to be acting in concert in relation to its affairs.

Identitii Limited – Declaration of Unacceptable Circumstances and Orders

The Panel has made a declaration of unacceptable circumstances (Annexure A) and final orders (Annexure B) in relation to an application dated 16 January 2026 by Mitchell Asset Management Pty Ltd as trustee for the Mitchell Asset Management Go‑Innovation Finance Fund in relation to the affairs of Identitii Limited (see TP26/003).

Background

Identitii is an ASX-listed company (ASX code: ID8).

Humm Group Limited – Panel Receives Application

The Panel has received an application from Akat Investments Pty Ltd in relation to the affairs of Humm Group Limited. 

Details of the application, as submitted by the applicant, are below.

A sitting Panel has not been appointed at this stage and no decision has been made whether to conduct proceedings.  The Panel makes no comment on the merits of the application.

Details

Humm is an ASX-listed company (ASX: HUM).

The applicant is a shareholder of Humm.

Mayne Pharma Group Limited

Introduction

  1. The Panel, Yasmin Allen AM (sitting President), Michael Borsky KC and Richard Phillips, made a declaration of unacceptable circumstances in response to an application by Mayne Pharma in relation to its affairs. Cosette proposed to acquire Mayne Pharma via a scheme of arrangement. The application concerned Cosette’s re-evaluation of its intentions in relation to Mayne Pharma’s Australian manufacturing site, which put the prospects of receiving FIRB approval of the scheme at risk.